ASX Announcement – 27 October 2026 $6.0 MILLION PLACEMENT OVERSUBSCRIBED BALANCE SHEET STRENGTHENED TO FUND THREE GROWTH PROGRAMMES Highlights • Firm commitments received for a $6.0M placement to institutional, professional + sophisticated investors at 7.2 cents per share, a 6.4% discount to...
$6.0 Million Placement Oversubscribed
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Resonance Health Ltd has announced the completion of an oversubscribed placement to raise funds from institutional investors, significantly strengthening its balance sheet. The placement will fully fund three growth programs over the next two years, focusing on clinical trials related to metabolic and obesity treatments. The company reported a substantial increase in net cash, which will support its operational and strategic initiatives moving forward. This announcement highlights the company's profitable performance and positive cash flow, reinforcing investor confidence in its growth strategy.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Resonance Health
- Liver Fibrosis Device - EPoC Study Results
- Trading Halt
- Notice of Annual General Meeting/Proxy Form
- Liver Fibrosis Device - Clinical Trial Results - Webinar
- AGM Date & Director Nomination Closing Date
Later from Resonance Health
- Proposed issue of securities - RHT
- Investor Presentation Liver Fibrosis Device & Capital Raise
- Liver Fibrosis Device Webinar Presentation
- TrialsWest East-Coast Expansion - Executive Appointment
- Application for quotation of securities - RHT
